Lori A. Gressick

3.2k total citations · 1 hit paper
13 papers, 1.7k citations indexed

About

Lori A. Gressick is a scholar working on Genetics, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Lori A. Gressick has authored 13 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Genetics, 9 papers in Pathology and Forensic Medicine and 6 papers in Oncology. Recurrent topics in Lori A. Gressick's work include Chronic Lymphocytic Leukemia Research (13 papers), Lymphoma Diagnosis and Treatment (9 papers) and HER2/EGFR in Cancer Research (3 papers). Lori A. Gressick is often cited by papers focused on Chronic Lymphocytic Leukemia Research (13 papers), Lymphoma Diagnosis and Treatment (9 papers) and HER2/EGFR in Cancer Research (3 papers). Lori A. Gressick collaborates with scholars based in Australia and United States. Lori A. Gressick's co-authors include John F. Seymour, Matthew S. Davids, Andrew W. Roberts, Rod Humerickhouse, Mary Ann Anderson, John M. Pagel, Brad S. Kahl, John F. Gerecitano, William G. Wierda and Sari H. Enschede and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Lori A. Gressick

13 papers receiving 1.7k citations

Hit Papers

Targeting BCL2 with Venetoclax in Relapsed Chronic Lympho... 2015 2026 2018 2022 2015 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
    2015 1.3k citations Andrew W. Roberts, Matthew S. Davids et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lori A. Gressick Australia 10 1.0k 772 605 474 447 13 1.7k
Monali Desai United States 7 950 0.9× 617 0.8× 533 0.9× 402 0.8× 446 1.0× 20 1.6k
Monica Else United Kingdom 22 1.6k 1.5× 1.2k 1.6× 428 0.7× 403 0.9× 320 0.7× 42 2.0k
Mariela Sivina United States 18 1.5k 1.4× 947 1.2× 649 1.1× 367 0.8× 471 1.1× 39 2.0k
Sílvia Marcé Spain 12 1.1k 1.1× 877 1.1× 458 0.8× 306 0.6× 240 0.5× 20 1.6k
Ilaria Del Giudice Italy 24 1.5k 1.4× 1.3k 1.6× 331 0.5× 408 0.9× 305 0.7× 82 1.9k
Peter Sportelli United States 18 737 0.7× 694 0.9× 652 1.1× 431 0.9× 332 0.7× 81 1.5k
Amber Gordon United States 8 1.2k 1.1× 792 1.0× 432 0.7× 340 0.7× 357 0.8× 14 1.5k
Nicole Lamanna United States 21 1.4k 1.3× 1.1k 1.5× 269 0.4× 343 0.7× 428 1.0× 113 1.8k
Antonella Zucchetto Italy 23 1.2k 1.2× 862 1.1× 492 0.8× 307 0.6× 244 0.5× 79 1.8k
Jerzy Z. Błoński Poland 21 797 0.8× 642 0.8× 224 0.4× 291 0.6× 151 0.3× 75 1.2k

Countries citing papers authored by Lori A. Gressick

Since Specialization
Citations

This map shows the geographic impact of Lori A. Gressick's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lori A. Gressick with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lori A. Gressick more than expected).

Fields of papers citing papers by Lori A. Gressick

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lori A. Gressick. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lori A. Gressick. The network helps show where Lori A. Gressick may publish in the future.

Co-authorship network of co-authors of Lori A. Gressick

This figure shows the co-authorship network connecting the top 25 collaborators of Lori A. Gressick. A scholar is included among the top collaborators of Lori A. Gressick based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lori A. Gressick. Lori A. Gressick is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Davids, Matthew S., Andrew W. Roberts, John F. Seymour, et al.. (2017). Venetoclax (VEN) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL).. Journal of Clinical Oncology. 35(15_suppl). e19041–e19041. 1 indexed citations
2.
Davids, Matthew S., Andrew W. Roberts, John F. Seymour, et al.. (2017). VENETOCLAX (VEN) IN PATIENTS WITH RELAPSED/REFRACTORY NON‐HODGKIN LYMPHOMA (NHL). Hematological Oncology. 35(S2). 203–204. 3 indexed citations
3.
Davids, Matthew S., Andrew W. Roberts, John F. Seymour, et al.. (2016). Safety, efficacy and immune effects of venetoclax 400 mg daily in patients with relapsed chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology. 34(15_suppl). 7527–7527. 11 indexed citations
4.
Roberts, Andrew W., Matthew S. Davids, John M. Pagel, et al.. (2015). Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. New England Journal of Medicine. 374(4). 311–322. 1337 indexed citations breakdown →
5.
Gerecitano, John F., Andrew W. Roberts, John F. Seymour, et al.. (2015). A Phase 1 Study of Venetoclax (ABT-199 / GDC-0199) Monotherapy in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma. Blood. 126(23). 254–254. 60 indexed citations
6.
Seymour, John F., Matthew S. Davids, John M. Pagel, et al.. (2014). ABT-199 (GDC-0199) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): High complete- response rate and durable disease control.. Journal of Clinical Oncology. 32(15_suppl). 7015–7015. 43 indexed citations
7.
Roberts, Andrew W., Shuo Ma, Danielle M. Brander, et al.. (2014). Determination of Recommended Phase 2 Dose of ABT-199 (GDC-0199) Combined with Rituximab (R) in Patients with Relapsed / Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). Blood. 124(21). 325–325. 38 indexed citations
8.
Davids, Matthew S., John F. Seymour, John F. Gerecitano, et al.. (2014). Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): Responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses.. Journal of Clinical Oncology. 32(15_suppl). 8522–8522. 75 indexed citations
9.
Seymour, John F., Matthew S. Davids, John M. Pagel, et al.. (2013). Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology. 31(15_suppl). 7018–7018. 20 indexed citations
10.
Davids, Matthew S., John F. Seymour, John F. Gerecitano, et al.. (2013). Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL).. Journal of Clinical Oncology. 31(15_suppl). 8520–8520. 10 indexed citations
11.
Davids, Matthew S., John F. Seymour, John F. Gerecitano, et al.. (2013). The Single-Agent Bcl-2 Inhibitor ABT-199 (GDC-0199) In Patients With Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Responses Observed In All Mantle Cell Lymphoma (MCL) Patients. Blood. 122(21). 1789–1789. 42 indexed citations
12.
13.
Davids, Matthew S., Andrew W. Roberts, Mary Ann Anderson, et al.. (2012). The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed Non-Hodgkin Lymphoma: Interim Results of a Phase I Study. Blood. 120(21). 304–304. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Monali Desai Breakdown of academic impact, for papers by Monica Else Breakdown of academic impact, for papers by Mariela Sivina Breakdown of academic impact, for papers by Sílvia Marcé Breakdown of academic impact, for papers by Ilaria Del Giudice Breakdown of academic impact, for papers by Peter Sportelli Breakdown of academic impact, for papers by Amber Gordon Breakdown of academic impact, for papers by Nicole Lamanna Breakdown of academic impact, for papers by Antonella Zucchetto Breakdown of academic impact, for papers by Jerzy Z. Błoński
Rankless by CCL
2026